Liquidity Mapping Around (RDNT) Price Events
This article analyzes Radnet Inc. (NASDAQ: RDNT), highlighting weak sentiment across all horizons and a mid-channel oscillation pattern. It identifies an exceptional 50.7:1 risk-reward short setup targeting 14.6% downside versus 0.3% risk. The analysis provides specific long, breakout, and risk hedging strategies, along with multi-timeframe signal analysis, including support and resistance levels.
RadNet, WIN-NextGen partner to introduce students to imaging careers
RadNet is collaborating with WIN-NextGen to introduce students and young adults to careers in medical imaging. The program will provide digital workforce platforms with learning modules, interactive experiences, mentorship, and shadowing opportunities for individuals aged 12-24 in Maryland, Washington, D.C., and parts of Virginia. The initiative is expected to expand to include internships and scholarships, with a launch event scheduled for October 24.
RadNet partners with WIN-NextGen on radiology workforce program
RadNet has announced a collaboration with WIN-NextGen to address the growing workforce shortage in medical imaging. The program will introduce middle school, high school, and young adult students to careers in radiology through digital learning modules, mentorship, and shadowing opportunities. The initiative aims to inspire more young people to enter the profession and will begin with participants earning rewards and eventually expanding to include internships and scholarships.
Students as young as 12 will explore medical imaging careers through mentors and center visits
RadNet (RDNT) has partnered with WIN-NextGen to introduce middle school, high school, and young adults aged 12-24 to careers in medical imaging. The program will offer digital learning modules, mentorship, and shadowing experiences in Maryland, Washington, D.C., and parts of Virginia, with future plans for internships and scholarships. This collaboration aims to address the growing workforce shortage in diagnostic imaging by inspiring the next generation of professionals.
RadNet and WIN-NextGen™ Form a Collaboration to Inspire the Next Generation of Medical Imaging Professionals
RadNet, Inc. has partnered with WIN-NextGen™ to address the growing workforce shortage in medical imaging by introducing careers in radiology to middle school, high school, and young adult learners. The collaboration will offer digital learning modules, interactive experiences, mentorship, and shadowing opportunities in Maryland, Washington D.C., and parts of Virginia. The program aims to inspire more students to pursue rewarding careers in radiology and strengthen the future imaging workforce.
RadNet stock trades at EUR 7.68 after Q2 revenue growth
RadNet reported strong Q2 2026 results with revenue growing 25.0% to USD 622.72 million and adjusted EPS reaching USD 0.29. Raymond James initiated coverage with a "Strong Buy" rating and a USD 95.00 price target, citing growth in imaging and the potential of its digital health business. Despite robust financial performance, the company's digital health segment continues to require significant investment, impacting margins.
RDNT: Radnet Inc Latest Stock Price, Analysis, News and Trading Ideas
The article provides current stock information for Radnet Inc (RDNT), showing its stock price and recent performance. It includes a neutral sentiment indicator and a user comment expressing dissatisfaction with Radnet's services. The content also features an advertisement for a premium service that removes ads.
Raymond James initiates RadNet stock coverage with strong buy rating
Raymond James has initiated coverage on RadNet Inc. (NASDAQ:RDNT) with a "Strong Buy" rating and a price target of $95.00, citing the company's leading growth in its core imaging segment and the additional optionality provided by its digital health franchise. Analyst Andrew Cooper highlighted RadNet's strong position to benefit from site neutral payment policies and its innovative use of digital and AI tools, despite the current overvaluation suggested by InvestingPro analysis and the digital health business weighing on margins. The initiation follows RadNet's impressive Q2 2026 results, which surpassed estimates and led to raised fiscal year guidance.
Raymond James initiates RadNet stock coverage with strong buy rating By Investing.com
Raymond James has initiated coverage on RadNet Inc. (NASDAQ:RDNT) with a Strong Buy rating and a $95.00 price target, citing the company's leading position in freestanding imaging and potential benefits from site-neutral payment policies. Analyst Andrew Cooper highlighted RadNet's strong growth in its core imaging segment and the underappreciated optionality of its digital health franchise. Despite InvestingPro suggesting the stock is overvalued, the company's nearly 19% revenue growth and recent strong Q2 2026 results support the positive outlook.
Raymond James initiates RadNet stock coverage with strong buy rating By Investing.com
Raymond James has initiated coverage on RadNet Inc. (NASDAQ:RDNT) with a Strong Buy rating and a $95.00 price target, aligning with the broader analyst consensus. The firm highlights RadNet's leading growth in its core imaging segment and the additional optionality provided by its digital health franchise, despite current valuation concerns. The company's recent Q2 2026 results surpassed Wall Street estimates, leading to raised fiscal year guidance.
RadNet, Inc. (RDNT) Stock Forecasts
The article "RadNet, Inc. (RDNT) Stock Forecasts" from Yahoo Finance appears to be a placeholder or an article that failed to load content. It displays an "Oops, something went wrong" message and contains only navigation links, market data, and disclaimers, with no actual content related to RadNet's stock forecast.
Hedgeye reiterates RadNet long idea (RDNT:NASDAQ)
Hedgeye has reiterated its long call on RadNet (RDNT), projecting a potential 30% upside. The firm believes RadNet's valuation is justified by several secular tailwinds, including the ongoing shift from inpatient to outpatient imaging, which could drive upside well into 2027.
Jefferies Maintains RadNet(RDNT.US) With Buy Rating, Raises Target Price to $96
Jefferies has reiterated its Buy rating for RadNet (RDNT.US) and increased the target price to $96. This adjustment reflects continued confidence in the company's performance and future prospects.
RadNet at Morgan Stanley conference: scale, AI and labor drive growth
RadNet discussed its growth strategy at the Morgan Stanley 24th Annual Global Healthcare Conference, emphasizing scale, technology (especially AI), and labor efficiency. The company highlighted that strong patient demand exists, but labor shortages are a primary constraint, which they are addressing through remote technologists, digital registration, and AI tools. RadNet also pointed to its fragmented market, potential benefits from site-neutral payment policies, and the increasing monetization of its DeepHealth AI unit as key growth drivers.
RadNet (RDNT) Stock May Be 23% Below Fair Value On Cash Flow
RadNet (RDNT) stock may be undervalued by as much as 23% based on its future cash flow generation. A Discounted Cash Flow (DCF) model suggests an intrinsic value meaningfully above the current share price of US$75.49, implying the market isn't fully reflecting the company's cash profile. Analyst narratives show a split view, with some seeing 19% undervaluation due to AI investments and others suggesting a 7% overvaluation given ongoing segment investments.
RadNet to Host Free Prostate Cancer Webinar on September 19, 2026
RadNet, Inc. announced it will host a free webinar on September 19, 2026, titled "Let’s Talk About It: Prostate Cancer: Your Questions Answered," in support of Prostate Cancer Awareness Month. The event will feature a radiologist, urologist, robotic surgeon, and a prostate cancer survivor to discuss screening, diagnosis, and treatment. This initiative aims to increase awareness and provide valuable information on prostate cancer, which is the second most common cancer among American men.
RadNet hires private equity firm leader as new CEO of its Digital Health Division
RadNet Inc. has appointed Kees Wesdorp, PhD, a leader from private equity firm Hellman & Friedman, as the new president and CEO of its Digital Health Division. Wesdorp, who previously held business leadership roles at Philips, will join RadNet's executive management team and oversee digital products and services in radiology informatics and AI. He will be based in the Netherlands and his employment term begins October 1st, with a significant compensation package including base salary, bonuses, and stock units.
Why (RDNT) Price Action Is Critical for Tactical Trading
This article analyzes Radnet Inc. (NASDAQ: RDNT) price action, suggesting a potential breakout and compelling upside. It provides institutional trading strategies, including long, breakout, and risk-hedging options, along with multi-timeframe signal analysis for tactical trading. The report highlights that no resistance levels remain above the current price, indicating significant upside potential for investors.
A Nashville presentation by RadNet will be webcast and archived
RadNet, Inc. announced that its Executive Vice President and Chief Strategy Officer, Dr. Greg Sorensen, will present at the Jefferies Healthcare Services Conference on September 15, 2026, in Nashville, Tennessee. The presentation will be webcast live and archived for later viewing on RadNet's website. RadNet is a national leader in diagnostic imaging services, operating numerous outpatient imaging centers across multiple states.
RadNet, Inc. to Present at the Morgan Stanley 24th Annual
RadNet, Inc. announced that its Executive Vice President and CFO, Mark Stolper, will present at the Morgan Stanley 24th Annual Global Healthcare Conference on Wednesday, September 16, 2026, at 7:45 a.m. Eastern Time. The presentation will be accessible via simultaneous and archived webcasts. RadNet is a leading national provider of diagnostic imaging services with over 11,000 employees.
RadNet, Inc. to Present at the Morgan Stanley 24th Annual Global Healthcare Conference on Wednesday, September 16th, 2026
RadNet, Inc. announced that its Executive Vice President and Chief Financial Officer, Mark Stolper, will present at the Morgan Stanley 24th Annual Global Healthcare Conference on September 16, 2026, at 7:45 a.m. Eastern Time. The presentation will be available via simultaneous and archived webcasts. RadNet is a national leader in diagnostic imaging services, operating a network of outpatient centers across multiple states and providing radiology information technology and AI solutions.
RadNet, Inc. to Present at the Morgan Stanley 24th Annual Global Healthcare Conference on Wednesday, September 16th, 2026
RadNet, Inc. announced that its Executive Vice President and Chief Financial Officer, Mark Stolper, will be presenting at the Morgan Stanley 24th Annual Global Healthcare Conference. The presentation is scheduled for Wednesday, September 16th, 2026, at 07:45 a.m. Eastern Time. A simultaneous and archived webcast of the presentation will be available for those unable to attend in person.
RadNet, Inc. to Present at the Jefferies Healthcare Services and Technology Conference on September 15, 2026
RadNet, Inc. announced that Dr. Greg Sorensen, Executive Vice President and Chief Strategy Officer, will present at the Jefferies Healthcare Services Conference on September 15, 2026. The presentation will occur at 9:10 a.m. Central Time in Nashville, TN, with simultaneous and archived webcasts available online. RadNet is a leading national provider of diagnostic imaging services with a network of outpatient imaging centers across multiple states.
RadNet, Inc. to Present at the Jefferies Healthcare Services and Technology Conference on September 15, 2026
RadNet, Inc. announced that Dr. Greg Sorensen, Executive Vice President and Chief Strategy Officer, will present at the Jefferies Healthcare Services Conference on September 15, 2026, at 9:10 a.m. Central Time. The presentation will be webcast live and archived on RadNet's website. RadNet is a national leader in diagnostic imaging services with extensive operations across multiple U.S. states and also provides radiology IT and AI solutions.
Countdown to RadNet (RDNT) Q2 Earnings: A Look at Estimates Beyond Revenue and EPS
RadNet (RDNT) is projected to announce Q2 earnings of $0.18 per share, a 41.9% decrease year-over-year, despite an expected revenue increase of 22.8% to $611.91 million. Analysts are also providing detailed estimates for specific revenue metrics, such as Imaging Center and Digital Health, which could offer deeper insights into the company's performance beyond the top and bottom lines. The stock holds a Zacks Rank #3 (Hold), suggesting a market-aligned performance in the near future.
RadNet, Inc. (RDNT) Stock Analysis: Exploring a Promising 20.90% Upside in Healthcare Diagnostics
RadNet, Inc. (RDNT), a leading healthcare diagnostics company, shows a promising 20.90% upside with a target price of $92.88, backed by strong analyst confidence. Despite challenges in profitability reflected by an EPS of -0.26 and a modest ROE of 1.50%, the company boasts impressive revenue growth and solid free cash flow. RadNet's strategic focus on AI-powered health informatics positions it as a high-risk, high-reward investment in the evolving diagnostic imaging and digital health sector.
Edmond DE Rothschild Holding S.A. Acquires Shares of 19,000 RadNet, Inc. $RDNT
Edmond DE Rothschild Holding S.A. acquired 19,000 shares of RadNet, Inc. (NASDAQ:RDNT) during the second quarter, valued at approximately $1.17 million. This acquisition contributes to institutional investors collectively owning 77.9% of the company. RadNet recently surpassed quarterly earnings expectations, reporting $0.29 EPS against a $0.20 consensus, and saw a 25% year-over-year revenue increase to $622.7 million.
RTW INVESTMENTS, LP Buys RadNet Inc (RDNT) -- Shares Look 11% Overvalued on GF Value
RTW INVESTMENTS, LP increased its stake in RadNet Inc (RDNT) by acquiring 561,958 shares at $61.67 each, bringing its total holdings to 4,846,958 shares and raising the stock's weight in its portfolio to 2.96%. RadNet, a diagnostic imaging service provider, is currently valued as "Modestly Overvalued" by GuruFocus with a GF Value of $69.37, despite its historical performance and institutional interest. The firm's decision to increase its position aligns with its healthcare-focused investment strategy, betting on the sector's continued growth despite mixed financial indicators for RadNet.
Robotti Robert Invests $7.46 Million in RadNet, Inc. $RDNT
Robotti Robert has initiated a significant position in RadNet, Inc. (NASDAQ:RDNT) during the second quarter, investing $7.46 million for 120,972 shares, which now constitutes 1.2% of the firm's portfolio. This move aligns with high institutional ownership in RadNet, including other major investors like BlackRock and RTW Investments increasing their stakes. The company recently reported strong financial results with quarterly revenue up 25% year-over-year and EPS exceeding analyst estimates, contributing to a "Moderate Buy" consensus among analysts.
Surging Revenue With Softer Profits Might Change The Case For Investing In RadNet (RDNT)
RadNet (RDNT) reported strong Q2 2026 revenue growth but a decline in net income and EPS, highlighting a tension between top-line expansion and profitability challenges. The company's investment narrative is centered on its AI-focused imaging platform, particularly the recent launch of Reporting Pro, which aims to increase volume but also requires significant investment, impacting current earnings. Analysts have varied opinions on RadNet's future profitability and fair value, with some optimistic about AI-driven margin gains, while others caution about the risks of new acquisitions and AI projects not meeting expected returns.
Bank of America Corp DE Boosts Position in RadNet, Inc. $RDNT
Bank of America Corp DE has increased its stake in RadNet, Inc. (NASDAQ:RDNT) by 15.1% in the first quarter, now owning 589,610 shares valued at approximately $33.0 million. Institutional investors collectively hold 77.9% of RadNet's stock. RadNet recently reported strong quarterly revenue of $622.7 million, a 25% year-over-year increase, and earnings of $0.29 per share, surpassing analyst expectations.
RadNet (NASDAQ:RDNT) Raised to "Hold" at Zacks Research
Zacks Research has upgraded RadNet (NASDAQ:RDNT) from a "strong sell" to a "hold" rating, though the overall analyst consensus remains a "Moderate Buy" with an $88 price target. The company recently reported strong quarterly results, beating EPS estimates with $0.29 and achieving a 25% year-over-year revenue increase to $622.72 million. Despite insider share sales, institutional investors hold a significant portion of RadNet's shares.
RadNet, Inc. 2026: Revenue $622.72M, EPS $0.1— 10-Q Summary
RadNet, Inc. reported its 2026 quarterly results with revenue of $622.72M, a 25% increase from the prior year, driven by growth in Imaging Centers and Digital Health. Despite revenue growth, net income attributable to common stockholders fell by 47.9% to $7.53M, resulting in a diluted EPS of $0.1. The company highlighted its Digital Health expansion, including acquisitions and increased DeepHealth customer base, and an expansion of its network to 442 centers with an 11% rise in procedural volumes.
RTW Investments (RDNT) discloses 4.8M-share, 6.2% ownership position in RadNet
RTW Investments, LP and Roderick Wong, M.D. have reported a beneficial ownership of 4,846,958 shares of RadNet, Inc. common stock, which represents a 6.2% stake in the company. This ownership is based on 78,634,236 shares outstanding as of May 8, 2026, with both parties holding shared voting and dispositive power over these shares. The shares are held directly by RTW-managed funds, entitling them to dividends and sale proceeds.
RadNet (NASDAQ: RDNT) files resale for 34,069 See-Mode milestone shares
RadNet Inc. (NASDAQ: RDNT) has filed to register for resale up to 34,069 shares of common stock. These shares are part of a contingent milestone payment to former shareholders of See-Mode Technologies Pte. Ltd. following its June 2, 2025 acquisition. The payment is tied to the achievement of specific FDA 510(k) milestones for a breast ultrasound detection product.
RadNet, Inc. (NASDAQ:RDNT) Receives Consensus Recommendation of "Moderate Buy" from Brokerages
RadNet, Inc. (NASDAQ:RDNT) has received a "Moderate Buy" consensus recommendation from nine brokerages, with an average 12-month price target of $88. The company recently reported strong quarterly results, exceeding EPS and revenue expectations, and its stock opened at $77.31. Insider transactions show recent stock sales by the CEO and a director, while institutional investors hold a significant portion of the shares.
RadNet (RDNT) Stock Cools As Record Revenue Meets Profit Pressure
RadNet (RDNT) experienced a slight stock dip despite reporting record Q2 2026 revenue of US$622.7m and US$99.7m in adjusted EBITDA, marking a 25% increase in total revenue year-over-year. While the core imaging business and digital health segment showed strong growth, net income and basic EPS roughly halved due to cost pressures, integration efforts, and interest expenses. The company's new US$250m term loan and insider selling also raise some concerns for investors.
RADNET, INC. : B. RILEY RAISES TARGET PRICE TO $96 FROM $83
B. Riley has increased its target price for RADNET, INC. (RDNT.O) to $96 from $83. This article, attributed to Reuters, provides this key financial update without further elaboration on the reasons for the target price adjustment. It includes a disclaimer noting that the content reflects only the author's opinion and is not investment advice.
RadNet (RDNT) Stock Cools As Record Revenue Meets Profit Pressure
RadNet (RDNT) experienced a slight stock dip despite reporting record Q2 2026 revenue of US$622.7m and US$99.7m in adjusted EBITDA, driven by strong growth in both its core imaging business and Digital Health segment. However, net income and EPS nearly halved due to cost pressures and investments, while the company also added a US$250m term loan. Investors are now weighing the company's significant top-line growth against its profitability pressures and increased leverage.
California Court Holds Sexual Orientation Harassment Claims Are Exempt from Arbitration Under the EFAA
A California appellate court has ruled that sexual orientation harassment claims are exempt from arbitration under the Ending Forced Arbitration of Sexual Assault and Sexual Harassment Act of 2021 (EFAA). This decision in Decloedt v. Radnet Management, Inc. affirms that harassment based on sexual orientation qualifies as sexual harassment under California's Fair Employment and Housing Act (FEHA), thereby triggering the EFAA's arbitration exemption. Employers are advised to review arbitration agreements, update anti-harassment policies, and ensure training addresses sexual orientation harassment to align with this evolving legal landscape.
RadNet (NASDAQ:RDNT) Stock Price Expected to Rise, Truist Financial Analyst Says
Truist Financial has increased its price target for RadNet (NASDAQ:RDNT) from $90 to $94, maintaining a "buy" rating, which implies a potential 24% upside. This follows RadNet's strong Q2 2026 performance, with revenue up 25% year-over-year to $622.7 million and EPS of $0.29, both exceeding estimates. The company also raised its 2026 guidance for revenue, adjusted EBITDA, and free cash flow due to high imaging demand and rapid growth in its Digital Health segment, despite some insider stock sales and a decline in year-over-year GAAP net income.
B. Riley Adjusts Price Target on RadNet to $96 From $83, Maintains Buy Rating
B. Riley has increased its price target for RadNet (RDNT) to $96 from $83, while reiterating a Buy rating on the stock. This adjustment comes amidst other analyst actions, including Truist also raising its price target for RadNet to $94 from $90. RadNet, a national provider of diagnostic imaging services, recently reported its Q2 2026 earnings.
E. Ohman J or Asset Management AB Increases Stock Position in RadNet, Inc. $RDNT
E. Ohman J or Asset Management AB significantly increased its stake in RadNet, Inc. by 1,144.3% in the second quarter, now owning 452,966 shares worth $27.9 million. This move comes as RadNet reported strong Q2 results with a 25% revenue increase and adjusted EPS exceeding expectations, leading to raised 2026 guidance. Despite some insider selling and mixed profitability metrics, analysts maintain a "Moderate Buy" consensus for the medical research company.
RadNet, Inc. Revenue Breakdown – FWB:PQIA
RadNet, Inc. generated 1.74 billion EUR in revenue last year, with its Imaging Center segment contributing the most at 1.69 billion EUR. The United States was the primary revenue source, accounting for 1.71 billion EUR. This information highlights the company's key revenue streams and geographic performance.
RadNet Q2 Earnings Call Highlights
RadNet (RDNT) reported record Q2 2026 revenue of $622.7 million and adjusted EBITDA of $99.7 million, driven by increased advanced imaging volumes, strategic acquisitions, and growth in its Digital Health segment. The company also announced FDA 510(k) clearance for its DeepHealth breast ultrasound AI solution and raised its imaging-center outlook for 2026.
RadNet, Inc. (RDNT) Investor Outlook: Capitalizing on a 23.99% Potential Upside in the Booming Diagnostics Sector
RadNet, Inc. (RDNT) is positioned as a significant player in the diagnostics sector with a market capitalization of $5.69 billion. Analysts project a 23.99% potential upside, driven by strong revenue growth (22.10%) and strategic investments in AI and DeepHealth OS. While the company shows a bullish trend with its stock price above moving averages and positive MACD, investors should note its high forward P/E ratio and current negative EPS when evaluating its financial health.
Earnings call transcript: RadNet tops Q2 2026 estimates, shares rise 6.1%
RadNet reported stronger-than-expected Q2 2026 results, with adjusted EPS of $0.29 and revenue of $622.7 million, exceeding analyst estimates. The company saw record total revenue and adjusted EBITDA, driven by growth in advanced imaging and digital health. Shares rose 6.09% in after-hours trading, and RadNet raised its full-year 2026 guidance for imaging center revenue, adjusted EBITDA, and free cash flow.
RadNet Jumps 8.2% on EPS Beat
RadNet shares surged 8.2% after the diagnostic imaging provider reported strong second-quarter earnings. The company posted an EPS of $0.29 on revenue of $622.7 million for the quarter ended June 2026, boosting its market capitalization to $6.0 billion. Investors will be watching if RadNet can maintain this positive earnings trajectory and capitalize on growth opportunities in the diagnostic imaging market.
RadNet touts ‘disproportionately higher’ growth in advanced imaging
RadNet Inc. reported "record" second-quarter results with a 25% year-over-year revenue increase, driven by disproportionately higher growth in advanced imaging procedures like MRI, CT, and PET/CT. The company revised its 2026 financial projections upwards, anticipating greater total net revenue and adjusted earnings, partly due to successful joint venture partnerships with hospital systems and the shift towards advanced modalities. RadNet attributed its success to increased procedural volumes, recent acquisitions, and growth in its digital health segment.
The Manufacturers Life Insurance Company Cuts Position in RadNet, Inc. $RDNT
The Manufacturers Life Insurance Company reduced its stake in RadNet, Inc. (NASDAQ:RDNT) by 35% in the first quarter, selling 18,543 shares and retaining 34,460 shares valued at $1.93 million. Despite a consensus "Moderate Buy" rating, analyst sentiment is mixed, with some downgrades and price target reductions. RadNet's Q1 revenue exceeded expectations, but the company reported an adjusted loss of $0.28 per share, missing anticipated results.
